Latest Conference Articles

October 3rd 2020, 5:22pm

NANETS Symposium

Increasing the dosage of lanreotide autogel from every 28 days to every 14 days led to encouraging progression-free survival outcomes in patients with progressive pancreatic and midgut neuroendocrine tumors.

October 3rd 2020, 10:00am

NANETS Symposium

Jonathan Strosberg, MD, discusse​s retreatment with Lutathera in advanced neuroendocrine tumors.

October 3rd 2020, 10:00am

NANETS Symposium

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses the role of ​Lutathera in neuroendocrine tumors.

October 2nd 2020, 10:09pm

NANETS Symposium

Marianne Pavel, MD, discusses the progression-free survival of patients with pancreatic and midgut neuroendocrine tumors who are treated with lanreotide autogel in the phase 2 CLARINET FORTE trial.

October 2nd 2020, 9:42pm

NANETS Symposium

Investigators are evaluating the combination of telotristat ethyl and Lutathera with a goal to improve progression-free survival in patients with well-differentiated neuroendocrine tumors in a randomized, phase 2 study that was highlighted during the 2020 NANETs Virtual Symposium.

October 2nd 2020, 9:20pm

NANETS Symposium

Longer-term data demonstrated that treatment with the radiopharmaceutical Lutathera continued to show low rates of toxicity among patients with somatostatin receptor–positive neuroendocrine tumors.

October 1st 2020, 4:16pm

ESMO Congress: Lung Cancer

Brigatinib demonstrated sustained improvements in overall and intracranial progression-free survival and health-related quality of life compared with crizotinib in patients with ALK-positive advanced non–small cell lung cancer.

September 29th 2020, 4:30pm

ESMO Congress

Plinabulin was found to be a more favorable option for the prevention of chemotherapy-induced neutropenia compared with pegfilgrastim during the coronavirus disease 2019 pandemic.

September 28th 2020, 10:47pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Daniel P. Petrylak, MD, discusses the pivotal trials that have led to the regulatory approvals of the PARP inhibitors olaparib and rucaparib in patients with metastatic castration-resistant prostate cancer and DNA repair mutations.

September 28th 2020, 10:18pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Benjamin P. Levy, MD, discusses the role of the combination of dabrafenib and trametinib in BRAF V600E-mutant non–small cell lung cancer.

September 28th 2020, 9:59pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Andre Goy, MD, MS, discusses how matching the right treatment with the right patient resides at the heart of precision medicine, but with continued interest in pursuing the molecular milieu of cancers, precision medicine has the potential to better inform pre- and post-cancer interventions as well.

September 28th 2020, 9:58pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Despite efforts to advance the precision oncology portfolio for patients with diffuse large B-cell lymphoma by categorizing subtypes of the molecularly heterogenous disease, developing treatment routes for these alternate forms presents an uphill battle.

September 28th 2020, 9:30pm

Dana-Farber Cancer Institute

Although frontline chemoimmunotherapy regimens have been the gold standard for patients with chronic lymphocytic leukemia for many years, the advent of BTK inhibitors and other novel drugs has moved the field toward adopting chemotherapy-free options for patients in this setting.

September 26th 2020, 4:00pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Efforts to leverage targeted therapy and immunotherapy, which have been approved modalities in advanced non–small cell lung cancer, are leading to improved survival in patients with advanced and earlier-stage disease.

September 26th 2020, 2:07pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Andre Goy, MD, MS, discusses updates in precision medicine. 

September 26th 2020, 1:30pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Natalie I. U. Vokes, MD, discusses the rise of predictive genomic biomarkers in oncology.

September 26th 2020, 1:00pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Over the past decade in gastrointestinal cancer treatment, the acknowledgement that cancer is heterogeneous and likely polyclonal has prompted a shift from gene testing for some patients, to many patients.

September 25th 2020, 9:25pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Natalie I. U. Vokes, MD, discusses investigative biomarkers of response to checkpoint inhibitors in the field of oncology.

September 25th 2020, 6:17pm

ESMO Congress: GU Cancers

With more than 4 years of follow-up, the health-related quality of life of men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy was shown to be maintained with the addition of apalutamide.

September 24th 2020, 10:30pm

ESMO Congress

Andrew B. Nixon, PhD, ​MBA, discusses the role of microsatellite instability in cancer.